KCNT1 and epilepsy: Reports of beneficial effects of quinidine in patients with KCNT1 mutations are increasing dramatically, supporting the use of quinidine in the treatment of epilepsy of infancy with migrating focal seizures (EIMFS), which is also known as migrating partial seizures of infancy (MPSI).